Surgery Websites
Transplant Surgery »  Meet the Team »  Pediatric Nephrology »  Anthony A. Portale, M.D.
Anthony A. Portale, M.D.

Anthony A. Portale, M.D.

Professor in Residence
Division of Pediatric Nephrology
Department of  Pediatrics
Director, Pediatric Dialysis Program

Contact Information

533 Parnassus Ave, UC Hall
San Francisco, CA, 94143 
Telephone  415-476-2423 
Fax  415-476-9976

Kidney Transplant Program (415) 353-8377
Renal Center (415) 476-2423
Open Popup
  • State University of New York at Buffalo 1974, M.D.
  • UCSF Medical Center, Pediatric Nephrology
  • American Board of Pediatrics - General Pediatrics
  • American Board of Pediatrics - Pediatric Nephrology Subspecialty
  • Acute Kidney Failure
  • Chronic Kidney Disease
  • End-Stage Renal Disease
  • Living Donor Kidney Transplantation
  • Pediatric bone and Mineral Disorders
  • Pediatric Kidney Transplantation
  • Pediatric Transplant Nephrology
  • Bone diseases in children
  • Genetic and acquired disorders of calcium
  • Pphosphorus and vitamin D metabolism

Dr. Anthony A. Portale, a pediatric kidney specialist, is director of the Pediatric Dialysis Program. He is an expert in genetic kidney and renal tubular diseases, disorder of bone and mineral metabolism, and acute kidney failure.

A graduate of St. Joseph's University in Philadelphia, he earned a medical degree at State University of New York at Buffalo and completed a pediatric nephrology fellowship at UCSF Medical Center. His research, funded by the National Institutes of Health, he has produced more than 80 publications in the medical and scientific literature focused on genetic and acquired disorders of calcium, phosphorus and vitamin D metabolism and bone diseases in children.

Publications provided by UCSF Profiles, powered by CTSI.
  1. Insogna KL, Rauch F, Kamenický P, Ito N, Kubota T, Nakamura A, Zhang L, Mealiffe M, San Martin J, Portale AA. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial. J Bone Miner Res. 2019 Dec; 34(12):2183-2191. View in PubMed
  2. Perwad F, Portale AA. Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD. Clin J Am Soc Nephrol. 2019 07 05; 14(7):1097-1099. View in PubMed
  3. Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, Crowley R, Jan De Beur S, Eastell R, Imanishi Y, Imel EA, Ing S, Ito N, Javaid M, Kamenicky P, Keen R, Kubota T, Lachmann R, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Zhang L, Theodore-Oklota C, Mealiffe M, San Martin J, Insogna K. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. Calcif Tissue Int. 2019 Sep; 105(3):271-284. View in PubMed
  4. Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019 06 15; 393(10189):2416-2427. View in PubMed
  5. Sohn WY, Portale AA, Salusky IB, Zhang H, Yan LL, Ertik B, Shahinfar S, Lee E, Dehmel B, Warady BA. Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to View in PubMed
  6. View All Publications


Site Directory